Analysts’ Price Target Changes for January, 4th (ABBV, ADJ, AT1, BB, BHGE, GLE, GOOGL, HSBA, INGA, INTC)

Analysts’ price target changes for Thursday, January 4th:

AbbVie (NYSE:ABBV) had its target price raised by Jefferies Group LLC from $115.00 to $120.00. Jefferies Group LLC currently has a buy rating on the stock.

ADO Properties (ETR:ADJ) was given a €50.00 ($59.52) price target by analysts at UBS Group AG. The firm currently has a buy rating on the stock.

AROUNDTOWN EO-,01 (ETR:AT1) was given a €7.00 ($8.33) target price by analysts at UBS Group AG. The firm currently has a buy rating on the stock.

BlackBerry (NYSE:BB) had its price target boosted by CIBC from $13.00 to $15.00. They currently have a positive rating on the stock.

Baker Hughes, a GE company Class A (NYSE:BHGE) had its target price lowered by Jefferies Group LLC from $38.00 to $35.00. Jefferies Group LLC currently has a hold rating on the stock.

Societe Generale (EPA:GLE) was given a €49.00 ($58.33) target price by analysts at UBS Group AG. The firm currently has a buy rating on the stock.

Alphabet (NASDAQ:GOOGL) had its price target raised by Cowen Inc from $1,150.00 to $1,230.00. The firm currently has an outperform rating on the stock.

HSBC (LON:HSBA) was given a GBX 725 ($9.69) target price by analysts at UBS Group AG. The firm currently has a neutral rating on the stock.

ING Groep (AMS:INGA) was given a €17.40 ($20.71) price target by analysts at UBS Group AG. The firm currently has a buy rating on the stock.

Intel (NASDAQ:INTC) was given a $44.00 price target by analysts at Royal Bank of Canada. The firm currently has a neutral rating on the stock.

The Coca-Cola (NYSE:KO) was given a $50.00 price target by analysts at Jefferies Group LLC. The firm currently has a neutral rating on the stock.

Aurubis (ETR:NDA) was given a €88.00 ($104.76) price target by analysts at Hauck & Aufhaeuser. The firm currently has a buy rating on the stock.

Onconova Therapeutics (NASDAQ:ONTX) was given a $6.00 target price by analysts at HC Wainwright. The firm currently has a buy rating on the stock. The analysts wrote, “Rigosertib Expanding Footprint; Moving Forward With CRADA to Address RASopathies Moving forward on RASopathies with NCI. Onconova announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the development of rigosertib in pediatric cancer associated RASopathies. The NCI is to conduct and fund the majority of research, including preclinical laboratory studies and a clinical trial, whereas Onconova is expected to provide rigosertib and initial funding for non-clinical studies. The studies are slated to start in 2018. The NCI is to focus on RASopathy related cancers in pediatric patients, whereas Onconova is expecting to focus on Juvenile Myelomonocytic Leukemia (JMML). This event signifies the potential expansion of rigosertib use in a number of cancers and syndromes driven by RAS pathway hyperactivation.””

Pacira Pharmaceuticals (NASDAQ:PCRX) was given a $54.00 price target by analysts at Royal Bank of Canada. The firm currently has a buy rating on the stock.

Pacira Pharmaceuticals (NASDAQ:PCRX) was given a $46.00 price target by analysts at Canaccord Genuity. The firm currently has a buy rating on the stock.

Revance Therapeutics (NASDAQ:RVNC) was given a $50.00 price target by analysts at Cantor Fitzgerald. The firm currently has a buy rating on the stock.

Banco Santander (BME:SAN) was given a €6.35 ($7.56) target price by analysts at UBS Group AG. The firm currently has a buy rating on the stock.

Sartorius (FRA:SRT3) was given a €78.00 ($92.86) price target by analysts at Kepler Capital Markets. The firm currently has a neutral rating on the stock.

Wal-Mart Stores (NYSE:WMT) was given a $100.00 target price by analysts at UBS Group AG. The firm currently has a neutral rating on the stock.

Receive News & Ratings for AbbVie Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply